TickerGuard
Buy Day today: Poor (57) Mixed market breadth · today: Nonfarm Payrolls (September)
TLPH

Talphera Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

1.10$ -3.4% vs. previous close Closing price · As of: Oct 1, 2026

Statements

Balance Sheet

All figures as a percentage of total assets in the same period.

Tick rows to compare them in a chart (up to 4)

Balance Sheet TLPH
Line item 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
– 92.5% 89.3% 84.6% 93.4% 95.7% 95.0% 88.3% 93.1% 89.1% 83.9% 89.6% 78.5% 70.6% 64.8% 51.7% 56.7% 51.6% 70.3%
– 26.8% 49.3% 44.7% 19.1% 74.3% 80.3% 69.5% 84.5% 80.3% 70.0% 73.0% 16.1% 41.1% 9.8% 32.2% 28.1% 48.6% 19.8%
– 89.1% 86.6% 53.9% 87.6% 92.6% 94.2% 87.2% 88.8% 80.3% 80.0% 87.7% 72.4% 64.7% 59.9% 33.2% 46.0% 48.6% 68.6%
– – – – – – – – 2.6% 5.8% 2.0% 0.3% 0.5% 1.0% 0.2% 0.7% – – –
– – – – – – – – 0.4% 2.2% 1.3% 0.7% 3.6% 2.5% 1.4% 2.5% – – –
– – – – – – – – – – – – – – – 18.6% 43.2% 48.4% 29.7%
– 247.0% 465.7% 1,064.7% 57.2% 47.5% 33.5% 46.0% 74.1% 105.3% 148.3% 96.5% 145.3% 184.1% 146.1% 54.1% 30.8% 56.1% 42.7%
– 20.0% 41.5% 196.4% 19.2% 22.2% 6.2% 15.9% 10.0% 10.2% 18.1% 13.2% 14.9% 26.6% 23.8% 29.0% 22.1% 14.5% 12.8%
– 12.5% 32.6% 175.8% 9.3% 11.5% – 7.9% 3.6% 4.2% 12.1% 9.7% 6.5% 14.9% 12.7% 14.9% – – –
– 5.2% 6.3% 8.0% 3.7% 3.5% 2.1% 2.8% 1.2% 1.6% 1.9% 1.7% 1.9% 4.1% 2.7% 2.6% 6.6% 3.7% 1.8%
– – – – – – – – – – – – 22.5% 19.8% 6.4% – – – –
– -147.0% -365.7% -964.7% 42.8% 52.5% 66.5% 54.0% 25.9% -5.3% -48.3% 3.5% -45.3% -84.1% -46.1% 45.9% 69.2% 43.9% 57.3%
– -150.4% -374.2% -1,003.9% -217.1% -189.1% -132.2% -206.9% -159.0% -246.4% -394.3% -286.2% -435.8% -661.4% -608.0% -896.7% -2,178.1% -2,507.3% -1,586.6%
– 4.5% 7.1% 15.1% 2.1% 1.7% 1.8% 2.6% 1.7% 2.3% 3.1% 2.4% 4.3% 6.4% 7.7% 15.6% 69.9% 141.7% 142.7%

Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?